Replimune Group, Inc.
RP1
advanced melanoma
Resolved
88days ago
FDA decision · Apr 10, 2026
What's at stake
An FDA complete response letter on RP1 for advanced melanoma is in focus around Apr 10, 2026.
Primary source
· SEC 8-K
verified 14h ago
“Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) – Replimune Group, Inc. (NASDAQ: REPL),”